Patient on life support in ICU

A new study shows that critically ill patients are not benefitting from antipsychotic medications that doctors have been using to treat delirium in patients in intensive care units. The evidence suggests doctors may need to re-examine the practice. Regenstrief investigator Babar Khan, M.D., was a co-author on the study.

Each year, more than seven million hospitalized patients in the United States develop delirium. The acute brain failure results in confusion and long-term memory problems.

The large study, MIND-USA (Modifying the INcidence of Delirium), sought to answer whether typical and atypical antipsychotics — haloperidol or ziprasidone — affected delirium, survival, length of stay or safety in ICU patients. Researchers screened nearly 21,000 patients at 16 U.S. medical centers. Of the 1,183 patients on mechanical ventilation or in shock, 566 became delirious and were randomized into groups receiving either intravenous haloperidol, ziprasidone or placebo (saline). Results showed that patients who received the drugs did not experience any improvements whatsoever in delirium, coma, length of stay or survival.

Study authors say the medicines are bringing risk and cost without benefit, based on the outcomes measured in this study. Doctors have been prescribing the drugs for 40 years.

Dr. Khan, who worked on this study, has conducted extensive studies on treating and preventing delirium. He led a project at Regenstrief that developed and validated the Confusion Assessment Method for the Intensive Care Unit 7. It’s an easy-to-use method to determine the severity of delirium.

The MIND-USA study was published in the New England Journal of Medicine. It was funded by the National Institute on Aging.

Related News

Jun 24, 2019 • Expert Opinion, News
Can Deprescribing Drugs Linked to Cognitive Impairment Actually Reduce Risk of Dementia?
JAMA Internal Medicine commentary highlights opportunity to discover modifiable risk factors for dementia In a commentary published in JAMA Internal Medicine, three Regenstrief Institute  research scientists write that while they and other researchers have identified a strong and consistent link between anticholinergic drugs and cognitive impairment from observational studies, randomized clinical trials represent the only…
Continue Reading >
Jun 18, 2019 • News
Regenstrief scientist explains how class of drugs may be related to dementia
Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show. Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia.…
Continue Reading >